|  | Albert, Jeffrey S.
Targets and Emerging Therapies for Schizophrenia
 1. Auflage Juli 2012
152,- Euro
2012. 486 Seiten, Hardcover
ISBN 978-0-470-32282-6 - John Wiley & Sons
Preis inkl. Mehrwertsteuer zzgl. Versandkosten.
|
Probekapitel
| Jetzt kaufen   
E-Books sind auch über alle bekannten E-Book Shops erhältlich.
|
| Kurzbeschreibung
This book provides a comprehensive resource for neuro-drug discovery and molecular targets for schizophrenia, from current therapies to evolving targets. The coverage begins with a discussion of prevalence and etiology, and an introduction to current therapies (which treat only certain, "positive" symptoms), as well as the rise of interest in addressing untreated symptoms. Subsequent sections focus on each major mechanistic hypothesis, beginning with a chapter that serves as an introduction and overview. Within these models, chapters focus on each major pharmacological target and address both the neurobiological and chemical aspects of that target.
Aus dem Inhalt
Preface vii
Contributors xi
Introduction 1
Alan J. Cross
1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective 5
Aurelija Jucaite and Svante Nyberg
2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37
Philip G. Strange
3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia 51
Kevin N. Boyd and Richard B. Mailman
4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85
Judith A. Siuciak and William J. Pitts
5 Glutamatergic Synaptic Dysregulation in Schizophrenia 115
Joseph T. Coyle, Alo Basu, and Michael Benneyworth
6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia 143
Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn
7 AMPA Receptor Positive Modulators 187
John A. Morrow, John K.F. Maclean, and Craig Jamieson
8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia 233
Jeffrey S. Albert and Michael W. Wood
9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255
Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones
10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273
Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross, and Karen L. Marquis
11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History 295
Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic
12 alpha7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia 319
Mihály Hajós and Bruce N. Rogers
13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia 355
Christian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu
14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381
Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson
15 GABA and Schizophrenia 425
John H. Kehne and George D. Maynard
Index 469
|
|
|
|
